This contract involves the procurement of a medication containing the active ingredient Velmanase alpha, in a dosage of 10 mg as a powder for infusion solution. The product is intended for intravenous use and is presented as a white to almost white powder. It is indicated for enzyme replacement ther
Contract awarded. Originally published 7 months ago.
Supply non-clinical consumables including forms, labels, and packaging for pathology and primary care services.
Procurement of RSV immunisation vaccine products for adult populations, scheduled for 2028.
Procurement for meningococcal ACWY vaccine supply in 2027 from qualified manufacturers or distributors.
Procurement opportunity for MMR vaccine supply with anticipated delivery timeline of 2027.
